Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Structure-Based Drug Discovery

Structure-Based Drug Discovery (SBDD) techniques available at Sygnature are able to guide our client projects to increased efficiency by minimizing the synthesis of unnecessary compounds.

SBDD involves the use of structural biology information to guide the design of new and improved compounds. Three-dimensional structural information is very valuable to map ligand interactions within the protein binding site and combined with computational techniques offers precious insights to advance drug design, and to move forward in the drug discovery process with more confidence.

  • Our expert scientists can apply SBDD techniques and use structural data at various stages of the project for hit identification, hit-to-lead and lead optimization.
  • We can offer a unique starting point for SBDD through fragment screening of our proprietary fragment library.
  • Our affiliation and close collaboration with Peak Proteins, offering protein production and X-ray crystallography, allows us to quickly obtain new 3D structural data to assess protein flexibility and feed back into the optimisation process.
  • We have extensive expertise in the use of computational techniques for structure-based drug design to exploit all the available structural information and help progress your series further.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.